You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PLOS this week: interaction of uracil-N-glycosylase and activation induced deaminase enzymes in B cell lymphoma, E. coli strains linked to bloodstream infections, and more.
Researchers analyzed viral samples from Boston early in the pandemic to study transmission events, including at a large international conference held there.
Researchers retraced clusters of related cases with epidemiology and deep sequencing of SARS-CoV-2 samples collected in Austria in the spring.
In PLOS this week: method to account for sequencing errors in phylogenies, study of influenza A in Switzerland, and more.
Research teams saw a significant number of SARS-CoV-2 infections during an aircraft carrier outbreak and in Marine recruits undergoing strict quarantine.
At the ASHG conference, a researcher described efforts to sequence SARS-CoV-2 genomes from Oregon to investigate introductions, super-spreader events, and viral biology.
In PLOS this week: immune-related gene pairs linked to malignant melanoma outcomes, plasticity among paramyxoviruses, and more.
Several Treponema sublineages cropped up after a large antibiotic campaign, though sequence data suggests resistance may have arisen only once.
With plasmid and chromosomal sequence data, European investigators identified three main routes for carbapenem antibiotic resistance spread in Klebsiella pneumoniae.
In PNAS this week: modeling of Rift Valley Fever spillover, Asian mosquito could pose malaria threat, and more.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.